DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/tkp4jp/premenstrual)
has announced the addition of the “Premenstrual
Syndrome – Pipeline Review, H2 2015” report to their offering.
This report provides comprehensive information on the therapeutic
development for Premenstrual Syndrome, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Premenstrual Syndrome and special features on late-stage and
The report enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Azevan Pharmaceuticals, Inc.
- DEKK-TEC, Inc.
M et P Pharma AG
- Pherin Pharmaceuticals, Inc.
- Umecrine Mood AB
- Small Molecule-1 to Antagonize GABAA Receptor for PMDD
Small Molecule-2 to Antagonize GABAA Receptor for PMDD
For more information visit http://www.researchandmarkets.com/research/tkp4jp/premenstrual
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716